Information  X 
Enter a valid email address
  Print          More announcements

Monday 21 March, 2022

Telix Pharmaceuticals Limited

EAU Updates Guidance for PSMA-PET Imaging

EAU Updates Guidance for PSMA-PET Imaging

MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate Cancer’ (the Guidelines) from the European Association of Urology (EAU), which demonstrate an increasing recognition of the clinical utility of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging modalities (PSMA PET), including gallium-68 PSMA-11, in the diagnosis of prostate cancer.1

The EAU Guidelines are dedicated to the development of clinical best practice for frontline urologists and to support shared decision making with patients, underpinning a shift towards more individualised patient care.

The EAU Guidelines recognise PSMA PET/CT as more accurate than CT and bone scan for the staging of high-risk prostate cancer, based on clinical data. Despite the increased sensitivity, the Guidelines acknowledge the lack of outcome data of subsequent treatment changes when using PSMA PET or whole-body MRI. The Guidelines further recommend lutetium-based PSMA therapy be offered to pre-treated metastatic castrate resistant prostate cancer (mCRPC) patients with one or more metastatic lesions, highly expressing PSMA (exceeding the uptake in the liver) on the diagnostic radiolabelled PSMA PET/CT scan.

Prof. Stefano Fanti, Director of Nuclear Medicine at the University of Bologna, said “The updated EAU Guidelines recognise that PSMA-PET imaging is more accurate than conventional imaging methods in prostate cancer initial staging, for high-risk disease. As opposed to NCCN,2 the EAU Guidelines underline the lack of outcome data of subsequent PSMA-PET treatment change. It sends a clear message of our quest for increased robustness and homogeneity in trials including PSMA-PET.”

Dr Colin Hayward, Telix Chief Medical Officer added “We are pleased the EAU continues to lead urology standards in Europe, acknowledging the importance of PSMA as a target, for improving sensitivity in assessing prostate cancer.

“We are focused on ensuring PSMA-PET imaging is widely available for patients across Europe, as we work towards European Marketing Authorisation Approvals for llluccix®.

“With Telix making PSMA PET more broadly available as we achieve approval in various markets, we look forward to contributing to the knowledge base around treatment changes based on PSMA PET.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead product, Illuccix® (kit for preparation of gallium-68 (68Ga) gozetotide (also known as 68Ga PSMA-11) injection) for prostate cancer imaging, has been approved by the U.S. Food and Drug Administration (FDA),3 and by the Australian Therapeutic Goods Administration (TGA).4 Telix is also progressing marketing authorisation applications for this investigational candidate in Europe5 and Canada.6

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: [email protected]

This announcement has been authorised for release by Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer.

Legal Notices

This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments.  Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.  

The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).  

____________________________________

1 European Association of Urology (EAU) Guidelines on Prostate Cancer. Limited Update March 2022. Available at: https://uroweb.org/guidelines/prostate-cancer.
2 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Sep 2021. Available at: https://www.nccn.org/guidelines/category_1.
3 ASX disclosure 20 December 2021.
4 ASX disclosure 2 November 2021.
5 ASX disclosure 10 December 2021.
6 ASX disclosure 16 December 2020.



a d v e r t i s e m e n t